To me it seems as though the company is looking to find the best/least dilutive way to fund EmtinB through phase I trials and then sell the business to big pharma.
That has been the view of the company way back when Brian Leedman was on the board. I recall him stating that big pharma most importantly want to make sure the drug is safe before acquiring it.
The pre clinical data is impressive and if it can prove to be safe in humans I don’t think they’d have any issues selling it. At these prices I find myself contemplating a re-entry.
NSB Price at posting:
5.5¢ Sentiment: None Disclosure: Not Held
